A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
A Multicenter Phase I Clinical Trial to Assess the Safety of Two Consecutive Days of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
Sponsor: SymBio Pharmaceuticals
A PHASE1 clinical study on Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, this trial is completed. The trial is conducted by SymBio Pharmaceuticals and has accumulated 8 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Nov 2020 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- SymBio Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .